Myelodysplastic Syndromes (MDS) Clinical Trials

9 recruiting

Frequently Asked Questions

Common questions about Myelodysplastic Syndromes (MDS) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 1Phase 2

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

Hodgkin LymphomaMultiple MyelomaAcute Myeloid Leukemia (AML)+7 more
M.D. Anderson Cancer Center80 enrolled1 locationNCT05092451
Recruiting
Phase 1

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

Acute Myelogenous LeukemiaMyelodysplastic Syndromes (MDS)
Beijing InnoCare Pharma Tech Co., Ltd.266 enrolled15 locationsNCT06656494
Recruiting
Early Phase 1

CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial

Myelodysplastic Syndromes (MDS)Precursor Cell Lymphoblastic Leukemia-LymphomaBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)+1 more
Institute of Hematology and Blood Transfusion, Czech Republic18 enrolled1 locationNCT06765876
Recruiting
Phase 2

Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor

Chronic Myeloid LeukemiaAcute Myeloid Leukemia (AML)Myelodysplastic Syndromes (MDS)+2 more
St. Petersburg State Pavlov Medical University60 enrolled1 locationNCT07238712
Recruiting
Early Phase 1

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Chronic Myeloid LeukemiaHodgkin LymphomaNon-Hodgkin Lymphoma+9 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins8 enrolled1 locationNCT06398457
Recruiting
Phase 2

Cord Blood Transplant in Adults With Blood Cancers

Non-Hodgkin's LymphomaAcute Myelogenous Leukemia (AML)Myelodysplastic Syndromes (MDS)+3 more
Memorial Sloan Kettering Cancer Center54 enrolled1 locationNCT05884333
Recruiting
Not Applicable

Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant

Multiple MyelomaLymphomaLeukemia+2 more
University of Nebraska88 enrolled1 locationNCT04898790
Recruiting
Not Applicable

Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies

Myelodysplastic Syndromes (MDS)Leukemia Acute Myeloid - AML
Assistance Publique Hopitaux De Marseille70 enrolled1 locationNCT06886425
Recruiting
Phase 1

A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

Acute Myeloid Leukemia (AML)Myelodysplastic Syndromes (MDS)
Ascentage Pharma Group Inc.102 enrolled14 locationsNCT04275518